NDLI: Seizing the strategic opportunities of emerging technologies by building up innovation system: monoclonal antibody development in China

Content Provider	Springer Nature : BioMed Central
Author	Zhang, Mao-Yu Li, Jian Hu, Hao Wang, Yi-Tao
Abstract	Background Monoclonal antibodies (mAbs), as an emerging technology, have become increasingly important in the development of human therapeutic agents. How developing countries such as China could seize this emerging technological opportunity remains a poorly studied issue in prior literature. Thus, this paper aims to investigate the research and development of mAbs in China based on an innovation system functions approach and probes into the question of how China has been taking advantage of emerging technologies to overcome its challenges of building up a complete innovation system in developing mAbs. Methods Mixed research methods were applied by combining archival data and field interviews. Archival data from the China Food and Drug Administration, Web of Science, the United States Patent and Trademark Office, the Chinese Clinical Trial Registry, and the National Science and Technology Report Service were used to examine the status quo of the technology and research and development (R&D) activities in China, while the opinions of researchers and managers in this field were synthesized from the interviews. Results From the perspective of innovation system functions, technological development of mAb in China is being driven by incentives such as the subsidies from the State and corporate R&D funding. Knowledge diffusion has been well served over the last 10 years through exchanging information on networks and technology transfer with developed countries. The State has provided clear guidance on search of emerging mAb technologies. Legitimacy of mAb in China has gained momentum owing to the implementation of government policies stipulated in the “The Eleventh Five-year Plan” in 2007, as well as national projects such as the “973 Program” and “863 Program”, among others. The potential of market formation stays high because of the rising local demand and government support. Entrepreneurial activities for mAb continue to prosper. In addition, the situation of resource supply has been improved with the support of the State. Conclusions This study finds that a complete innovation system for mAb has begun to take shape in China. MAb innovators in China are capitalizing on this emerging technological opportunity to participate in the global drive of developing the value chain for the innovative drug. In the long run, the build-up of the research system for mAb in China could bring about more driving forces to the mAb innovation system.
Related Links	https://health-policy-systems.biomedcentral.com/counter/pdf/10.1186/s12961-015-0056-1.pdf
Ending Page	12
Page Count	12
Starting Page	1
File Format	HTM / HTML
ISSN	14784505
DOI	10.1186/s12961-015-0056-1
Journal	Health Research Policy and Systems
Issue Number	1
Volume Number	13
Language	English
Publisher	BioMed Central
Publisher Date	2015-11-04
Access Restriction	Open
Subject Keyword	Health Administration R & D Technology Policy Medicine Public Health Health Services Research Health Policy China Emerging technology Innovation system Monoclonal antibody R & D/Technology Policy Medicine/Public Health
Content Type	Text
Resource Type	Article
Subject	Health Policy
Journal Impact Factor	3.6/2023
5-Year Journal Impact Factor	4.3/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Seizing the strategic opportunities of emerging technologies by building up innovation system: monoclonal antibody development in China

Author's report Title : Seizing the strategic opportunities of emerging technologies by innovation system functioning : monoclonal antibody ( mAb ) development in China Version : 1 Date : 3 April 2015

Key factors for national spread and scale-up of an eConsult innovation

Public satisfaction with health system after healthcare reform in China

Emergence of biopharmaceutical innovators in China, India, Brazil, and South Africa as global competitors and collaborators

Promoting the creation of R&D intentions in primary healthcare measured by a validated instrument

Building health research systems to achieve better health

Direct from the COVID-19 crisis: research and innovation sparks in Brazil

Advancing the application of systems thinking in health: managing rural China health system development in complex and dynamic contexts

Seizing the strategic opportunities of emerging technologies by building up innovation system: monoclonal antibody development in China

Similar Documents

Seizing the strategic opportunities of emerging technologies by building up innovation system: monoclonal antibody development in China

Author's report Title : Seizing the strategic opportunities of emerging technologies by innovation system functioning : monoclonal antibody ( mAb ) development in China Version : 1 Date : 3 April 2015

Key factors for national spread and scale-up of an eConsult innovation

Public satisfaction with health system after healthcare reform in China

Emergence of biopharmaceutical innovators in China, India, Brazil, and South Africa as global competitors and collaborators

Promoting the creation of R&D intentions in primary healthcare measured by a validated instrument

Building health research systems to achieve better health

Direct from the COVID-19 crisis: research and innovation sparks in Brazil

Advancing the application of systems thinking in health: managing rural China health system development in complex and dynamic contexts

Seizing the strategic opportunities of emerging technologies by building up innovation system: monoclonal antibody development in China